The most-often-cited examples of the possible relationship between short-acting β2-AR agonists and mortality in asthma were the startling rise in asthma deaths in several countries, including the UK, Australia and New Zealand during the early 1960s [144] and in New Zealand in the late 1970s [145,146]. This evidence concerns the gene ADRB2 and asthma.